Yue Huang MD, Qin Yu PhD, Elaine Tan Su Yin MD, Guoqing Wei PhD, Wenjun Wu PhD, Alex H. Chang PhD, He Huang PhD, Yongxian Hu PhD
{"title":"HLA-matched allogeneic anti-CD19 CAR-T therapy in treating a relapsed/refractory acute lymphoblastic leukemia patient with high tumor burden","authors":"Yue Huang MD, Qin Yu PhD, Elaine Tan Su Yin MD, Guoqing Wei PhD, Wenjun Wu PhD, Alex H. Chang PhD, He Huang PhD, Yongxian Hu PhD","doi":"10.1002/imed.1032","DOIUrl":null,"url":null,"abstract":"<p>The genetically engineered chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR-T cell products in patients with high tumor burden and prior tumor-reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor-derived HLA-matched allogeneic CAR-T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR-T therapy.</p>","PeriodicalId":73348,"journal":{"name":"Immunomedicine","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2022-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/imed.1032","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immunomedicine","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/imed.1032","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The genetically engineered chimeric antigen receptor T cell (CAR-T) therapy has shown remarkable clinical efficacy in the treatment of hematological malignancies. Nonetheless, it is difficult to harvest adequate autologous T cells to manufacture potent CAR-T cell products in patients with high tumor burden and prior tumor-reductive treatment. Here we reported a relapsed/refractory acute lymphoblastic leukemia patient with high leukemia burden and central nervous system (CNS) involvement. The patient responded to donor-derived HLA-matched allogeneic CAR-T treatment, with the achievement of quick complete remission. And for the first time, we revealed the development of a cerebral CRS in situ after allogeneic CAR-T therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
